GlassScriptPhysician profile
Badal Raval
NPI 1427009653
$2,586.74
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $455 · 2020: $295 · 2021: $199 · 2022: $465 · 2023: $744 · 2024: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100 · Education: $71.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.26 |
| Education | $71.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $542.60 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $369.58 | 2019-2024 | Farxiga |
| Fresenius USA Marketing, INC. | $214.55 | 2019-2024 | Velphoro |
| Otsuka America Pharmaceutical, INC. | $198.20 | 2023-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $191.78 | 2021-2024 | |
| Vifor Pharma, INC. | $188.60 | 2019-2023 | Veltassa |
| Travere Therapeutics, INC. | $150.57 | 2023 | |
| Amgen INC. | $110.73 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $102.18 | 2021-2024 | Acthar, Terlivaz |
| Bard Peripheral Vascular, INC. | $100.69 | 2019 | |
| Opko Pharmaceuticals, LLC | $94.42 | 2020-2023 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $58.34 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.67 | 2023-2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $38.32 | 2022-2024 | Lupkynis |
| Lexicon Pharmaceuticals, INC. | $34.65 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.82 | 2023-2024 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $24.46 | 2023 | Tarpeyo |
| Alnylam Pharmaceuticals INC. | $23.57 | 2024 | Onpattro |
| Alexion Pharmaceuticals, INC. | $21.43 | 2019 | |
| Mallinckrodt Enterprises LLC | $17.43 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.18 | 2019 | |
| Horizon Therapeutics Plc | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Badal Raval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.